ClinicalTrials.gg
Active, not recruitingNCT01988883Updated Jan 15, 2026

Modafinil and Cognitive Function in POTS

An Early Phase 1 interventional study of Placebo and Modafinil in Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Vanderbilt University Medical Center · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.

Enrollment
11th of 13
20 · median 40
Started
2014
the only one that year
Phase 1
5 of 18
none open now
Primary completion
2026-12
later than 5 of 12 live
Registered
6th of 18
by date

Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 6th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

A common complaint among patients with Postural Tachycardia Syndrome (POTS) is "brain fog" or difficulty concentrating. This problem is poorly understood.

The purpose of this study is to better understand the cognitive dysfunction associated POTS, and to determine optimal treatment strategies for this condition. In this study, the investigators will test the hypothesis that acute administration of the psychostimulant drug modafinil can improve seated measures of cognitive function in patients with POTS.

Read the detailed description

Postural Tachycardia Syndrome (POTS) is one of the most frequent forms of chronic orthostatic intolerance and affects an estimated 500,000 people in the United States alone. This disorder is a common source of disability in young adults, with a strong predilection for premenopausal women. POTS is characterized by an excessive increase in heart rate (>30 bpm) on assuming the upright position that is associated with orthostatic symptoms that are relieved by lying down. These symptoms include palpitations, chest pain, lightheadedness or dizziness, blurred vision, nausea and fatigue. In addition, POTS patients commonly report mental clouding or "brain fog" even while lying down or seated, which can pose significant limitations to daily life.

Although mental clouding is an almost universal complaint among POTS patients, this phenomenon is poorly understood. As a result, the optimal treatment strategies to manage cognitive dysfunction in this condition remain unknown. The purpose of this study is to better define the mental clouding associated with POTS and to determine whether the psychostimulant modafinil is a viable therapeutic option to improve cognitive function in these patients. The investigators hypothesize that acute modafinil administration will improve seated measures of cognitive function in POTS patients. The specific aims are:

  1. To assess whether acute modafinil improves seated measures of cognitive function, particularly measures of attention and executive function, in POTS patients compared to placebo.
  2. To assess whether propranolol, either alone as an active control or in combination with modafinil to mitigate potential heart rate increases, can improve cognitive function in POTS.

Patients will be studied on 4 separate days with oral administration of: placebo, modafinil (200 mg), propranolol (20 mg) and the combination of modafinil (200 mg) and propranolol (20 mg). The order of administration will be randomized in a double-blind manner. Patients will be seated during the study and cognitive testing will begin approximately 2.5 hours after medication administration. Cognitive testing will consist of the CogState computerized brief battery. Patients will also be asked to stand for 10 minutes (or as long as tolerated) at 1, 3 and 4 hours post medication, with some of the cognitive tests repeated while standing at the 4 hour time point.

03

Conditions studied

  • Postural Tachycardia Syndrome

Keywords

  • Postural Tachycardia Syndrome
  • Tachycardia
  • Orthostatic Intolerance
  • Autonomic Nervous System Diseases
  • Primary Dysautonomias
  • Nervous System Diseases
  • Cardiovascular Diseases
  • Modafinil
  • Propranolol
  • Neurobehavioral Manifestations
  • Neurologic Manifestations
  • Cognitive Symptoms
  • Neuropsychological Tests
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females of all races between the ages of 18 to 60 years
  • Diagnosed with POTS by the Vanderbilt Autonomic Dysfunction Center based on the following consensus criteria:(a) an increase in heart rate ≥ 30 beats per minute within 10 minutes of changing from the supine to standing position; (b) absence of orthostatic hypotension (defined as a decrease in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg upon standing); and (c) chronic symptoms (≥ 6 months) consistent with POTS that are worse with standing and are relieved by lying down
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Overt causes for POTS such as acute dehydration and bed rest deconditioning
  • Patients taking serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors
  • Known allergies or to study medications
  • Pregnancy or breast-feeding
  • Inability to give or withdraw
  • Other factors which in the investigator's opinion would prevent the subject from completing the study protocol such as poor compliance during previous studies
  • Asthma (due to the contraindication of propranolol for asthma patients)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.

    Drug: Placebo

  • Experimental
    Modafinil

    Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.

    Drug: Placebo · Drug: Modafinil

  • Experimental
    Propranolol

    Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.

    Drug: Placebo · Drug: Propranolol

  • Experimental
    Modafinil plus Propranolol

    Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.

    Drug: Modafinil · Drug: Propranolol

Interventions

  • DrugPlacebo

    Locking gelatin capsules filled with microcrystalline cellulose

  • Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.

    Also known as: Provigil

  • Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.

    Also known as: Inderal, Inderal LA, Innopran XL

06

What researchers measure

Primary outcomes

  1. Visual Attention Performance Speed

    This outcome will be assessed using the CogState Identification Task which provides a continuous variable for visual attention performance speed.

    Time frame: 2.5 hours post study medication

Secondary outcomes

  1. Executive Function

    This outcome will be assessed by the CogState Groton Maze Learning and Set-Shifting Tasks which provides continuous variables for speed and accuracy measures of executive function.

    Time frame: 2.5 hours post study medication

  2. Blood Pressure

    This outcome will be assessed using an automated sphygmomanometer arm cuff.

    Time frame: Baseline and up to 4 hours after drug administration

  3. Heart Rate

    This outcome will be assessed using an automated sphygmomanometer arm cuff.

    Time frame: Baseline and up to 4 hours after drug administration

Other outcomes

  1. Processing speed

    This outcome will be assessed by the CogState Detection task which provides continuous variables for speed and accuracy measures of processing speed.

    Time frame: 2.5 hours post study medication

  2. Visual learning and memory

    This outcome will be assessed by the CogState One Card Learning task which provides continuous variables for speed and accuracy measures of visual learning and memory.

    Time frame: 2.5 hours post study medication

  3. Working memory

    This outcome will be assessed by the CogState One-Back task which provides continuous variables for speed and accuracy measures of working memory.

    Time frame: 2.5 hours post study medication

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2014 (actual). Primary completion is estimated for Dec 2026, 146 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2013
First posted
Nov 20, 2013
StartActual
Oct 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01988883
Responsible party
Italo Biaggioni (Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Nov 20, 2013
Start date
Oct 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

Italo Biaggioni, M.D.
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Modafinil · Propranolol

Start the discussion